VirNext provides a large panel of solutions and deliverables in the fields of viral production (see virus production) and evaluation of anti-viral compounds (see virology). For more information please contact us.

SARS-CoV-2


Several variants of concern :

  • Alpha (B.1.1.7) , detected first in United Kingdom
  • Beta (B.1.351), detected first in South Africa
  • Gamma (P.1), detected first in Brazil
  • Delta (B.1.617.2), detected first in India

 

Several variants of interest :

  • Wuhan-like
  • D614G mutation (Spike)

Viral quantification


  • Quantification of infectious viral particles: plaque assay (PFU)
  • End-point dilution quantification: 50% tissue cell infectious dose  (TCID50) assay 
  • Genome viral quantification: RT-qPCR real-time 

Vaccine response assays


  • Immunization and infectious challenge (in vivo models, partnership with Cynbiose)
  • Humoral response characterization: microneutralization (MN)
  • Viral titration (nasal wash and lungs)
  • Cytokine evaluation

Evaluation of candidate compounds


  • In vitro models (human and animal cell lines and reconstituted human airway epithelium, partnership with Epithelix)
  • In vivo models, partnership with Cynbiose (please contact us)

For more information, see virolgy.